Literature DB >> 25758236

[Therapy of overactive bladder (OAB)].

M Kurosch1, R Mager, K Gust, M Brandt, H Borgmann, A Haferkamp.   

Abstract

Overactive bladder (OAB) is a symptom complex which is present in approximately 17% of the European population. It is observed in the presence or absence of incontinence (wet or dry) and is associated with a high degree of psychological stress as well as high costs for the healthcare system. Myogenic, urothelial and neurogenic factors lead to frequently unknown changes of muscular, neural and connective tissue. For the definition, etiology and diagnostics of the disease the previous continuing medical education (CME) article "Diagnosis of overactive bladder (OAB)" should be consulted. In recent years some improvements have been made in OAB-related research, in terms of pathophysiological models and new pharmacological approaches with the development of new therapeutic agents. Besides classical substances, recently approved agents are increasingly being used for the therapy of OAB. Furthermore, non-pharmaceutical approaches and surgical techniques still play an important role in the therapy of OAB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25758236     DOI: 10.1007/s00120-015-3770-y

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  44 in total

1.  Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group.

Authors:  R A Schmidt; U Jonas; K A Oleson; R A Janknegt; M M Hassouna; S W Siegel; P E van Kerrebroeck
Journal:  J Urol       Date:  1999-08       Impact factor: 7.450

2.  Therapeutic effect of multiple resiniferatoxin intravesical instillations in patients with refractory detrusor overactivity: a randomized, double-blind, placebo controlled study.

Authors:  Hann-Chorng Kuo; Hsin-Tzu Liu; Wen-Chin Yang
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450

3.  Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.

Authors:  Jennifer Lee; Selina Moy; John Meijer; Walter Krauwinkel; Taiji Sawamoto; Virginie Kerbusch; Donna Kowalski; Michael Roy; Alan Marion; Shin Takusagawa; Marcel van Gelderen; James Keirns
Journal:  Clin Drug Investig       Date:  2013-06       Impact factor: 2.859

4.  Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).

Authors:  Douglas G Tincello; Sara Kenyon; Keith R Abrams; Christopher Mayne; Philip Toozs-Hobson; David Taylor; Mark Slack
Journal:  Eur Urol       Date:  2012-01-05       Impact factor: 20.096

5.  Effect of intravesical Resiniferatoxin (RTX) on lower urinary tract symptoms, urodynamic parameters, and quality of life of patients with urodynamic increased bladder sensation.

Authors:  Apostolos Apostolidis; Gwendoline E Gonzales; Clare J Fowler
Journal:  Eur Urol       Date:  2006-05-04       Impact factor: 20.096

Review 6.  Muscarinic receptor subtypes in the lower urinary tract.

Authors:  Daniel Giglio; Gunnar Tobin
Journal:  Pharmacology       Date:  2009-03-19       Impact factor: 2.547

7.  OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial.

Authors:  Victor W Nitti; Roger Dmochowski; Sender Herschorn; Peter Sand; Catherine Thompson; Christopher Nardo; Xiaohong Yan; Cornelia Haag-Molkenteller
Journal:  J Urol       Date:  2012-12-14       Impact factor: 7.450

8.  OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.

Authors:  Christopher Chapple; Karl-Dietrich Sievert; Scott MacDiarmid; Vik Khullar; Piotr Radziszewski; Christopher Nardo; Catherine Thompson; Jihao Zhou; Cornelia Haag-Molkenteller
Journal:  Eur Urol       Date:  2013-04-10       Impact factor: 20.096

9.  Urodynamic effects of the bladder C-fiber afferent activity modulation in chronic model of overactive bladder in rats.

Authors:  K Juszczak; A Ziomber; M Wyczolkowski; P J Thor
Journal:  J Physiol Pharmacol       Date:  2009-12       Impact factor: 3.011

10.  OnabotulinumtoxinA significantly attenuates bladder afferent nerve firing and inhibits ATP release from the urothelium.

Authors:  Valerie M Collins; Donna M Daly; Marina Liaskos; Neil G McKay; Donna Sellers; Christopher Chapple; David Grundy
Journal:  BJU Int       Date:  2013-08-13       Impact factor: 5.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.